DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ ...
As the Consumer Electronics Show 2025 kicks off in Las Vegas, it’s clear that artificial intelligence is no longer just a buzzword—it’s becoming an integral part of our daily lives in ways we might ...
The global fetal monitoring market revenue was around US$ 3.6 billion in 2023 and is estimated to reach US$ 6.2 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.2% during the ...